CD274 and triple-negative breast carcinoma: <i>Conclusions:</i> As a result, alterations in PD-L1<sup>+</sup> myeloid cells and immune infiltration can be associated with atezolizumab and paclitaxel therapy success in triple-negative breast cancer.